&w=3840&q=100)
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India.
The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years.
Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies.
Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections.
The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26.
Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China.
Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia.
Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions.
In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially.
The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
41 minutes ago
- Hindustan Times
US Supreme Court allows DOGE access to Social Security data
The US Supreme Court on Friday allowed the Department of Government Efficiency, billionaire Elon Musk's former department, broad access to the Social Security Administration's data systems. This will allow the DOGE to access personal information of millions of Americans logged under the SSA, news agency Reuters reported. Justices put on hold the order of Maryland-based US District Judge Ellen Hollander, who had largely blocked DOGE's access to "personally identifiable information" in data such as medical and financial records while litigation proceeded in a lower court. This move came at the Justice Department's request. The court, which had a 6-3 conservative majority, did not provide a rationale for siding with the DOGE. Two labor unions and an advocacy group sued to stop DOGE from accessing sensitive data at the SSA. The plaintiffs of the lawsuit argued that SSA had been "ransacked" and that DOGE members had been installed at the agency without proper vetting or training and demanded access to some of its sensitive data systems. Earlier in February, DOGE's move to seek access to SSA data prompted the acting commissioner, Michelle King, to step down against the backdrop of the Musk-security system issues. King chose to resign after over 30 years of service as she refused to provide the requested information to the DOGE staffers at the SSA. A day later, the White House had said that the Trump administration put an "anti-fraud expert" temporarily in charge at the SSA. At the time, Trump also directed Musk and DOGE to identify fraud at the agency, with White House press secretary Karoline Leavitt saying that several dead people have been receiving fraudulent Social Security payments. "They haven't dug into the books yet, but they suspect that there are tens of millions of deceased people who are receiving fraudulent Social Security payments and so their goal in going into the Social Security Administration is to identify three things: Number one, to identify duplicate payments and to end them, Number two, to identify payments that are going to deceased people who are no longer living and should no longer be receiving that money and number three, to protect the integrity of the system for hardworking Americans who have been paying into it their entire lives,' Leavitt had told Fox News. Nancy Altman, president of the Social Security Works, an advocacy group for the preservation of Social Security benefits, said that there is no way to overstate "how serious a breach this (DOGE seeks SSA data) is". "And my understanding is that it has already occurred. The information collected and held securely by the Social Security Administration is highly sensitive," she had added. SSA has the data of everyone with a Social Security number, Medicare, and every low-income American who has applied for Social Security's means-tested companion program, Supplemental Security Income. In addition, Social Security payments account for around $1.5 trillion, or a fifth, of the annual federal spending in the US. An audit from last year, a NYT report cited. The agency is a major provider of government benefits, sending checks each month to more than 70 million recipients including retirees and disabled Americans.
Time of India
42 minutes ago
- Time of India
City Docs Save Woman With Congenital Heart Defect Without Open Surgery
Nagpur: In a groundbreaking development, Nagpur-based doctors performed a rare and highly advanced heart procedure that saved a young woman's life — without open heart surgery. The patient, born with a complex congenital heart defect known as Blue baby syndrome (Tetralogy of Fallot or TOF), a condition wherein a baby's skin turns bluish due to lack of oxygen in blood, had undergone a major open-heart surgery as a child. Now an adult, she recently became severely unwell due to a leaking heart valve and needed another major surgery. Instead of undergoing another high-risk open-heart operation, she received a minimally invasive treatment — much like angioplasty — through a vein in her leg. Incredibly, the patient was able to walk and talk just an hour after the procedure and was ready to go home within 24 hours. This life-saving and rare procedure, known as Transcatheter Pulmonary Valve Implantation, was successfully carried out by Dr Manish Chokhandre, senior interventional paediatric cardiologist at Arneja Heart Institute. "Redo open-heart surgeries are extremely risky, especially in adults with childhood congenital heart conditions," explained Dr Chokhandre. "We carefully studied the patient's unique heart structure, custom-designed a special valve, and performed the entire procedure without opening the chest. " Welcoming the advancement, Dr Amar Amale, president of Cardiological Society of India (CSI), Vidarbha chapter, said, "Gone are the days when children had to undergo open-heart surgery with large chest incisions. Paediatric cardiology has advanced to a level where even a complex congenital heart condition in an adult, who earlier had childhood surgery, can now be treated through a simple leg vein — just like an angioplasty. It's a huge leap in cardiac care." "Paediatric cardiology needs more attention. One in every 100 children is born with a heart defect. Many go undiagnosed or are diagnosed too late," said Dr Chokhandre, who regularly performs heart procedures on newborns. Veteran cardiologist Dr Jaspal Arneja said, "Thanks to medical advances and new technologies, even complex heart problems can be treated more safely. With artificial intelligence (AI) helping us understand heart function better, we can now offer more accurate and effective treatment." This successful case from Nagpur brings hope to hundreds of children and adults born with heart defects — and shows how medical science and skillful execution are transforming lives, one heartbeat at a time. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Mint
an hour ago
- Mint
Paul Weiss Loses Ex-US Attorney Williams After Trump Deal
A former federal prosecutor who joined Paul Weiss in the month leading up to President Trump's second term left for Jenner & Block. New York-based partner Damian Williams will co-chair Jenner's litigation department and investigations, compliance and defense practice, according to the firm's announcement on Friday. He leaves a firm that struck a controversial deal with the Trump administration to avoid punitive sanctions to a firm that sued Trump to block a similar attack. Williams' departure comes only months after he re-joined Paul Weiss Rifkind Wharton & Garrison. Paul Weiss announced Williams' arrival in January, and said he began his legal career as a Paul Weiss associate in 2009. 'Damian led the Southern District with excellence and integrity, and we are excited to welcome him to Jenner as part of our firm's long tradition of hiring former public servants who are zealous and effective advocates,' said Jenner's chair Tom Perrelli, former Associate US Attorney General. A representative for Paul Weiss thanked Williams for his contributions to the firm and wished him well. Paul Weiss roused controversy within the legal community as the first of nine firms to pledge a collective $940 million in free legal services to Trump-approved causes in exchange for avoiding punitive White House sanctions. The firm drew Trump's anger as the former professional home to Mark Pomerantz, who left the firm in 2021 to assist with the Manhattan District Attorney's investigation into Trump's finances. Along with other Trump-targeted firms Perkins Coie, WilmerHale and Susman Godfrey, Jenner sued the Trump administration to reclaim security clearances and access to federal buildings that were threatened by a Trump executive order. Williams served as the US Attorney for the Southern District of New York from 2021 to 2024, when he left to join Paul Weiss. He oversaw the high-profile prosecutions of FTX founder Sam Bankman-Fried and US Senator Bob Menendez. He was the first Black US Attorney in the history of the New York Southern District. Jenner's announcement said Williams will be a 'driving force' in the firm's litigation and white-collar work. 'Jenner & Block fearlessly advocates for its clients and provides outstanding strategic counsel through their most difficult challenges,' Williams said. 'I've seen firsthand how this firm expertly tackles the toughest cases and lives its values. I'm excited to join a team with an extraordinary depth of legal talent that doesn't shy away from hard fights—and delivers results that matter.' Paul Weiss has sustained a string of partner exits in the wake of the announcement of its deal with the Trump administration. Litigation department co-chair Karen Dunn, an outside counsel to Google and former campaign adviser to Kamala Harris, left with three partners last month to start a new litigation boutique. Dunn and colleagues have represented Apple Inc. and Facebook. Their exits followed Jeh Johnson, Homeland Security Secretary under President Barack Obama, and Steve Banks, who oversaw the firm's pro bono practice. Trump issued an executive order against the firm March 14, which he rescinded within a week when firm chairman Brad Karp said the firm would devote $40 million in free legal services to mutually-agreed upon causes during Trump's presidency. Karp's pledge was expanded upon by Skadden, Arps, Slate, Meagher & Flom's March 28 deal with the president, which saw the firm promise $100 million in free legal services. Within a month, seven other firms, including Kirkland & Ellis and Latham & Watkins, made similar pledges, some as high as $125 million. The firms, as part of their deals, also promised not to engage in 'illegal DEI' activities and commit to 'merit-based' hiring. Skadden also faced departures in the wake of its deal with Trump, one being Kathleen Rubenstein, executive director of the Skadden Foundation, resigning from the public interest law group. To contact the reporter on this story: Justin Henry in Washington DC at jhenry@ To contact the editors responsible for this story: Chris Opfer at copfer@ John Hughes at jhughes@ Alessandra Rafferty at arafferty@ This article was generated from an automated news agency feed without modifications to text.
